Clinical Trial in FSGS (kIDNEY Disease)
A clinical trial is being conducted to see if an investigational study drug may help people with FSGS. The trial is testing different doses of the study drug for safety, effectiveness, and side effects in patients with FSGS. The study drug or a placebo will be taken as a capsule by mouth one (1) time every day for about 12 weeks.
This trial will help determine if the investigational drug reduces proteinuria (increased levels of protein in the urine) while maintaining stable kidney function in adults with FSGS. Throughout the course of the trial, researchers will measure how different doses of the investigational drug impact proteinuria and carefully evaluate kidney‐related and other effects of the drug.
The trial is sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. and
approved under Advarra IRB Protocol #(Pro00059817)
Who may be eligible?
• FSGS confirmed by kidney biopsy or documentation of TRPC6 gene mutation
• 18‐75 years of age
• GFR > 30 ml/min
• Urine protein ≥1000 mg/g creatinine at screening
Note: There are additional requirements study volunteers must meet to qualify for the study
The Participant may receive:
• Close supervision by expert specialists
• Reimbursement for time and travel
• Medical screening and blood tests
Contact us.
Thank you for considering participating in this clinical trial for FSGS. If you or someone you know is interested and meets the eligibility criteria, please contact us for more information. Eligible participants may receive compensation and medical support at no cost.